Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

New NICE incontinence guidance specifies first-choice antimuscarinics

  • Print
  • Comment
  • Save

ui

NICE has recommended three antimuscarinics as first-line options for female urinary incontinence in its updated guidance.

Oxybutynin, tolterodine and darifenacin are recommended first-line in their immediate-release formulations, although darifenacin is once daily.

Only if the first choice is not effective or well tolerated can alternative antimuscarinics be used - including extended release formulations - and the choice should be based on acquisition cost.

Transdermal oxybutynin is reserved for women unable to tolerate oral medication.

Today Pulse Learning launched Guideline debrief: female urinary incontinence, a CPD module which uses three typical primary care case histories to get you up-to-speed with all the new guideline recommendations most relevant to GPs.

 

Have your say

  • Print
  • Comment
  • Save